Sprouty genes function in suppression of prostate tumorigenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 49, 2012, Pages 20023-20028

  Schutzman, Jennifer L ^a   Martin, Gail R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; HETEROZYGOSITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMORIGENESIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPROUTY GENE; TUMOR SUPPRESSOR GENE;

ANIMALS; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE; GENES, TUMOR SUPPRESSOR; HISTOLOGICAL TECHNIQUES; IN SITU HYBRIDIZATION; LASER CAPTURE MICRODISSECTION; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PTEN PHOSPHOHYDROLASE; RAS PROTEINS;

EID: 84870583628     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217204109     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29.
2. Whang YE, et al. (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95(9):5246-5250. (Pubitemid 28208583)
3. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95(26):15587-15591. (Pubitemid 29018743)
4. Wang S, et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4(3):209-221. (Pubitemid 37163835)
5. Trotman LC, et al. (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1(3):E59.
6. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59(2):279-284. (Pubitemid 29048852)
7. Gioeli D (2005) Signal transduction in prostate cancer progression. Clin Sci (Lond) 108 (4):293-308.
8. Palanisamy N, et al. (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16(7):793-798.
9. Mason JM, Morrison DJ, Basson MA, Licht JD (2006) Sprouty proteins: Multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol 16(1):45-54. (Pubitemid 43077094)
10. Cabrita MA, Christofori G (2008) Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis 11(1):53-62.
11. Taylor BS, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11-22.
12. Lo TL, et al. (2006) Sprouty and cancer: The first terms report. Cancer Lett 242(2): 141-150. (Pubitemid 44515046)
13. Fritzsche S, et al. (2006) Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer 13(3):839-849. (Pubitemid 44763260)
14. Shaw AT, et al. (2007) Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 21(6):694-707. (Pubitemid 46440291)
15. Minowada G, Miller YE (2009) Overexpression of Sprouty 2 in mouse lung epithelium inhibits urethane-induced tumorigenesis. Am J Respir Cell Mol Biol 40(1):31-37.
16. Lee SA, et al. (2008) Integration of genomic analysis and in vivo transfection to identify Sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology 47(4):1200-1210. (Pubitemid 351547906)
17. Grieshammer U, Agarwal P, Martin GR (2008) A Cre transgene active in developing endodermal organs, heart, limb, and extra-ocular muscle. Genesis 46(2):69-73. (Pubitemid 351498175)
18. Basson MA, et al. (2005) Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell 8(2):229-239. (Pubitemid 40197739)
19. Shim K, Minowada G, Coling DE, Martin GR (2005) Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Dev Cell 8(4):553-564. (Pubitemid 40450744)
20. Basson MA, et al. (2006) Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1. Dev Biol 299(2):466-477. (Pubitemid 44740419)
21. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19(4):348-355. (Pubitemid 28357906)
22. Freeman D, et al. (2006) Genetic background controls tumor development in PTEN-deficient mice. Cancer Res 66(13):6492-6496. (Pubitemid 44085602)
23. Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev 24(18):1967-2000.
24. Basson MA, et al. (2008) Specific regions within the embryonic midbrain and cerebellum require different levels of FGF signaling during development. Development 135(5):889-898. (Pubitemid 351524143)
25. Maddison LA, Nahm H, DeMayo F, Greenberg NM (2000) Prostate specific expression of Cre recombinase in transgenic mice. Genesis 26(2):154-156. (Pubitemid 30158106)
26. Wu X, et al. (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101(1-2):61-69. (Pubitemid 32186310)
27. McKie AB, et al. (2005) Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 24(13):2166-2174. (Pubitemid 40516583)
28. Kwabi-Addo B, et al. (2004) The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 64(14):4728-4735. (Pubitemid 38924514)
29. Mulholland DJ, et al. (2012) Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res 72(7):1878-1889.
30. Pearson HB, Phesse TJ, Clarke AR (2009) K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res 69(1):94-101.
31. Wang J, et al. (2012) B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 72(18):4765-4776.
32. Majumder PK, et al. (2003) Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc Natl Acad Sci USA 100(13):7841-7846. (Pubitemid 36760057)
33. GaoH, et al. (2006)Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 103(39):14477-14482. (Pubitemid 44484775)
34. Kwabi-Addo B, Ren C, Ittmann M (2009) DNA methylation and aberrant expression of Sprouty1 in human prostate cancer. Epigenetics 4(1):54-61.
35. Darimipourain M, Wang S, Ittmann M, Kwabi-Addo B (2011) Transcriptional and posttranscriptional regulation of Sprouty1, a receptor tyrosine kinase inhibitor in prostate cancer. Prostate Cancer Prostatic Dis 14(4):279-285.
36. Kang MR, et al. (2012) Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth. Cancer Res 72(19):5069-5079.
37. Klein OD, et al. (2006) Sprouty genes control diastema tooth development via bidirectional antagonism of epithelial-mesenchymal FGF signaling. Dev Cell 11(2):181-190. (Pubitemid 44159239)
38. Dankort D, et al. (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5):544-552.